Championing the Consumer: Millennium's New Vitivity Health Information Business
This article was originally published in Start Up
When Millennium Pharmaceuticals contemplates creating a new business, it must be on the premise that it change medical practice. Vitivity Inc., a newly formed, wholly owned subsidiary, is one business that could do so: an attempt to integrate personalized medical information to improve the effectiveness and efficiency of care. But unlike the physician drivers of change in Millennium's core drug business, consumers will have to drive the change Vitivity will enable.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.